Revance Therapeutics Sees FY23 R&D Expenses $75M-$85M
Portfolio Pulse from Benzinga Newsdesk
Revance Therapeutics has projected its research and development (R&D) expenses for the fiscal year 2023 to be between $75 million and $85 million.
November 08, 2023 | 11:05 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Revance Therapeutics' projected R&D expenses for FY23 could impact its financial performance and potentially its stock price.
The projected R&D expenses for FY23 are a significant part of Revance Therapeutics' budget. This could impact the company's financial performance, which in turn could affect its stock price. However, R&D investments can also lead to new product developments, which could positively impact the company's future revenues and stock price.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100